By Clinical Research News Staff 

June 11, 2025 | In case you were wondering, Jensen Huang’s favorite pre-trained generative AI models are ChatGPT, Perplexity, and Gemini Pro: “These three models I use them interchangeably,” the founder and CEO of NVIDIA said today at a GTC presentation in Paris. But these models offer only some of the foundational capabilities that agentic AI offers businesses, he said.  

Today, IQVIA announced multiple AI orchestrator agents in collaboration with NVIDIA. These specialized agentic systems—covering trial start-up, target identification, clinical data review, and more—are designed to manage and accelerate drug development workflows for IQVIA customers. 

Today, Huang called it, “the world’s largest automation platform for clinical trials.”  

In Paris, Huang acknowledged all of the weaknesses of pre-trained AI models—hallucinations, limited training datasets, giving up on reasoning tasks that take too long. But all of these “one-shot” AI models dedicated to retrieval, augmented generation, web search, and multimodal understand were necessary to arrive at agentic AI, which Huang called “a giant step function from one-shot AI.”  

Through an example outlining how to set up a food truck business in Paris, Huang predicted a future where each company will build its own agents to orchestrate tasks such as market research, financial forecasting, operations planning, and marketing.  

“You’re going to be hiring agents,” he predicted. “You’re going to need specialized agents on specialized tools and specialized skills.” NVIDIA offers a platform for building such specialized agents—the NVIDIA AI Enterprise software platform—and IQVIA is now launching a suite of orchestrator AI agents for the clinical trials industry.  

The entire model is trained on specialized IQVIA life sciences data. In it, orchestrator AI agents act as supervisors for specialized sub-agents, routing actions— like speech-to-text transcription, clinical coding, structured data extraction and data summarization—to the appropriate sub-agent, ensuring that each step in the complex workflow is accelerated. The process, the companies said, is managed by human experts in the loop. 

Orchestrator agents focus on various steps in the clinical trial process, according to the NVIDIA blog post announcing the collaboration.  

• IQVIA’s clinical trial start-up AI orchestrator agent addresses the growing need for acceleration in clinical trial timelines. The agent directs its sub-agents to analyze clinical trial protocols and extract critical participant inclusion and exclusion criteria, using reasoning to solve these problems in phased steps.
  
• The target identification AI orchestrator agent builds a knowledge base from research articles and biomedical databases, using customized AI models to identify key relationships among the data and extract insights. 
  
• The clinical data review agent uses a set of automated checks and specialized sub-agents to catch data issues early, reducing the data review process from seven weeks to as little as two weeks. 

“From molecule to market, AI promises to be transformative for life sciences and healthcare,” said Avinob Roy, vice president and general manager of product offerings for commercial analytics solutions at IQVIA, in the blog post.  

Agentic Paths for Drug Commercialization 

IQVIA is also launching post-approval agents to speed market research and pharmaceutical sales. “There are a lot of different components — market dynamics, patient behaviors, access challenges and the competitive landscape — that you need to triangulate to really understand where the bottlenecks are,” Roy said. 

• IQVIA market landscape orchestrator agents can provide a comprehensive understanding of how a treatment will reach patients by analyzing patient records, prescriptions, and lab results in just a few days instead of weeks.
  
• The IQVIA field companion orchestrator agent can equip pharmaceutical sales teams before each engagement with healthcare providers. By integrating physician demographics, digital behavior, prescribing patterns and patient dynamics, the agent helps field teams prepare for physician meeting using near real-time insights, leading to more engaging and impactful discussions. 

“The collective impact of these agents across numerous commercial workflows brings unprecedented precision and operational efficiency to the life sciences, supporting better experiences and outcomes for healthcare professionals and patients,” Roy said.